Here's Why Investors Should Retain STERIS (STE) Stock for Now
https://www.zacks.com/stock/news/2232656/here-s-why-investors-should-retain-steris-ste-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2232656
Feb 27, 2024 - Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
0
Quest Diagnostics' (DGX) New Pact to Reduce Food Insecurity
https://www.zacks.com/stock/news/2232652/quest-diagnostics-dgx-new-pact-to-reduce-food-insecurity?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2232652
Feb 27, 2024 - Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.
0
HAE or SYK: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2232605/hae-or-syk-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2232605
Feb 27, 2024 - HAE vs. SYK: Which Stock Is the Better Value Option?
0
Here's Why You Should Buy Edward Lifesciences (EW) Stock Now
https://www.zacks.com/stock/news/2231893/here-s-why-you-should-buy-edward-lifesciences-ew-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2231893
Feb 26, 2024 - Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.
0
ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand
https://www.zacks.com/stock/news/2230458/icon-iclr-q4-earnings-surpass-estimates-margins-expand?cid=CS-ZC-FT-analyst_blog|earnings_article-2230458
Feb 22, 2024 - ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.
0
Here's Why You Should Retain Align Technology (ALGN) Stock Now
https://www.zacks.com/stock/news/2229514/here-s-why-you-should-retain-align-technology-algn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2229514
Feb 21, 2024 - Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.
0
Charles River (CRL) Gains From CRADL Amid Soft Market Scenario
https://www.zacks.com/stock/news/2229453/charles-river-crl-gains-from-cradl-amid-soft-market-scenario?cid=CS-ZC-FT-analyst_blog|zer_report_update-2229453
Feb 21, 2024 - Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
0
Sight Sciences (SGHT) to Expand in Europe With New Launch
https://www.zacks.com/stock/news/2229444/sight-sciences-sght-to-expand-in-europe-with-new-launch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2229444
Feb 21, 2024 - By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.
0
Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up
https://www.zacks.com/stock/news/2228769/medtronic-mdt-q3-earnings-beat-estimates-2024-view-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2228769
Feb 20, 2024 - Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.
0
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
https://www.zacks.com/stock/news/2228766/here-s-why-investors-should-retain-resmed-rmd-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2228766
Feb 20, 2024 - Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.
0